/MXCT
MXCT Stock - MaxCyte, Inc.
Healthcare|Medical - DevicesNASDAQ
$1.31-3.31%
$0.04 (-3.31%) • Jan 13
66
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.3
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+356.3%upside
Target: $6.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for MXCT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.30 – $1.33
TARGET (TP)$6.00
STOP LOSS$1.21
RISK/REWARD1:44.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.36
52W High$5.20
52W Low$1.26
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $38.63M | $41.29M | $44.26M | $33.89M | $26.17M |
| Gross Profit | $31.53M | $36.55M | $39.16M | $30.25M | $23.40M |
| Gross Margin | 81.6% | 88.5% | 88.5% | 89.2% | 89.4% |
| Operating Income | $-51,197,000 | $-48,299,000 | $-27,361,000 | $-18,188,600 | $-11,056,700 |
| Net Income | $-41,055,000 | $-37,923,000 | $-23,571,000 | $-19,082,200 | $-11,816,400 |
| Net Margin | -106.3% | -91.8% | -53.3% | -56.3% | -45.2% |
| EPS | $-0.39 | $-0.37 | $-0.19 | $-0.22 | $-0.18 |
Company Overview
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
50%
Hold / Neutral
1
50%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
1 Bullish1 Neutral/Bearish
Price Targets
$7
Average Target
↑ 394.3% Upside
Now
$6
Low
$7
Average
$7
High
Based on 2 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 11th 2025 | BTIG Research | Downgrade | Neutral | - |
| August 7th 2025 | William Blair | Downgrade | Market Perform | - |
| July 22nd 2025 | Stephens | Initiation | Overweight | $6 |
| November 29th 2023 | Craig Hallum | Initiation | Buy | $7 |
Earnings History & Surprises
MXCTBeat Rate
50%
Last 18 quarters
Avg Surprise
+13.7%
EPS vs Estimate
Beats / Misses
9/3
6 met exactly
Latest EPS
$-0.12
Q4 2025
EPS Surprise History
Q1 24
+50.0%
$-0.05vs$-0.10
Q2 24
+35.7%
$-0.09vs$-0.14
Q3 24
+35.7%
$-0.09vs$-0.14
Q4 24
+15.4%
$-0.11vs$-0.13
Q1 25
+16.7%
$-0.10vs$-0.12
Q2 25
0.0%
$-0.10vs$-0.10
Q3 25
-20.0%
$-0.12vs$-0.10
Q4 25
-9.1%
$-0.12vs$-0.11
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 10, 2026 | $-0.08 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.11 | $-0.12 | -9.1% | ✗ MISS |
Q3 2025 | Aug 6, 2025 | $-0.10 | $-0.12 | -20.0% | ✗ MISS |
Q2 2025 | May 7, 2025 | $-0.10 | $-0.10 | 0.0% | = MET |
Q1 2025 | Mar 11, 2025 | $-0.12 | $-0.10 | +16.7% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $-0.13 | $-0.11 | +15.4% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $-0.14 | $-0.09 | +35.7% | ✓ BEAT |
Q2 2024 | May 7, 2024 | $-0.14 | $-0.09 | +35.7% | ✓ BEAT |
Q1 2024 | Mar 12, 2024 | $-0.10 | $-0.05 | +50.0% | ✓ BEAT |
Q4 2023 | Nov 8, 2023 | $-0.10 | $-0.11 | -10.0% | ✗ MISS |
Q3 2023 | Aug 9, 2023 | $-0.10 | $-0.10 | 0.0% | = MET |
Q2 2023 | May 10, 2023 | $-0.11 | $-0.11 | 0.0% | = MET |
Q1 2023 | Mar 15, 2023 | $-0.06 | $-0.05 | +16.7% | ✓ BEAT |
Q4 2022 | Nov 9, 2022 | $-0.09 | $-0.06 | +33.3% | ✓ BEAT |
Q3 2022 | Aug 10, 2022 | $-0.08 | $-0.08 | 0.0% | = MET |
Q2 2022 | May 9, 2022 | $-0.07 | $-0.04 | +42.9% | ✓ BEAT |
Q1 2022 | Mar 22, 2022 | $-0.05 | $-0.05 | 0.0% | = MET |
Q4 2021 | Nov 10, 2021 | $-0.05 | $-0.03 | +40.0% | ✓ BEAT |
Q3 2021 | Sep 13, 2021 | $-0.05 | $-0.05 | 0.0% | = MET |
Q3 2021 | Jul 30, 2021 | — | $-0.09 | — | — |
Latest News
MaxCyte Reports Q4 Revenue Around $6.7M Vs $9.3M Est, Full-Year Revenue Near $30M Vs $35.41M Est
📉 NegativeBenzinga•Jan 12, 2026, 01:18 PM•Also:
MaxCyte CFO Douglas Swirsky To Transition From Role In H1 2026
➖ NeutralBenzinga•Nov 12, 2025, 09:17 PM
MaxCyte Affirms FY2025 Sales Guidance of $29.261M-$32.512M vs $36.402M Est
📉 NegativeBenzinga•Nov 12, 2025, 09:10 PM
MaxCyte Q3 EPS $(0.12) Misses $(0.11) Estimate, Sales $6.829M Miss $8.370M Estimate
📉 NegativeBenzinga•Nov 12, 2025, 09:09 PM
MaxCyte Reports Preliminary Q3 Revenue of $6.8M And Reiterates Its 2025 Revenue Guidance
➖ NeutralBenzinga•Nov 5, 2025, 01:24 PM
MaxCyte Signs Strategic Platform License Agreement With Moonlight Bio To Advance T Cell Therapy Development
📈 PositiveBenzinga•Oct 6, 2025, 12:07 PM
MaxCyte shares are trading higher after the company announced it reduced its global workforce by 34%.
📉 NegativeBenzinga•Sep 23, 2025, 05:59 PM
MaxCyte Restructures Operations, Reduces Global Workforce By 34% To Unlock ~$13.6M In Annual Savings
📉 NegativeBenzinga•Sep 22, 2025, 08:33 PM
Frequently Asked Questions about MXCT
What is MXCT's current stock price?
MaxCyte, Inc. (MXCT) is currently trading at $1.31 per share. The stock has moved -3.31% today.
What is the analyst price target for MXCT?
The average analyst price target for MXCT is $6.00, based on 1 analyst.
What sector is MaxCyte, Inc. in?
MaxCyte, Inc. operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the NASDAQ exchange.
What is MXCT's market cap?
MaxCyte, Inc. has a market capitalization of $0.14 billion, making it a small-cap company.
Does MXCT pay dividends?
No, MaxCyte, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorARMP
Armata Pharmaceuticals, Inc.
$6.22
Mkt Cap: $0.2B
AVR
Anteris Technologies Global Corp.
$4.41
Mkt Cap: $0.1B
CATX
Perspective Therapeutics, Inc.
$2.58
Mkt Cap: $0.2B
LNSR
LENSAR, Inc.
$11.60
Mkt Cap: $0.1B
NNOX
Nano-X Imaging Ltd.
$2.96
Mkt Cap: $0.2B
OWLT
Owlet, Inc.
$14.24
Mkt Cap: $0.2B
PRE
Prenetics Global Limited
$15.97
Mkt Cap: $0.2B
PROF
Profound Medical Corp.
$8.68
Mkt Cap: $0.3B
SGMO
Sangamo Therapeutics, Inc.
$0.44
Mkt Cap: $0.1B
TLSI
TriSalus Life Sciences, Inc.
$5.90
Mkt Cap: $0.2B
Explore stocks similar to MXCT for comparison